New hope for advanced cancers: experimental drug ACR-2316 enters first human trial
NCT ID NCT06667141
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 prior treatments and are still in fairly good health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ACR-2316
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors who have limited other choices.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. It is tested in a small group, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact
-
Carolina BioOncology Institute
RECRUITINGHuntersville, North Carolina, 28078, United States
Contact
Contact
-
Denver Health One
RECRUITINGDenver, Colorado, 80218, United States
Contact
Contact
-
Florida Cancer Specialist
RECRUITINGSarasota, Florida, 34232, United States
Contact
Contact
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92663, United States
Contact
Contact
-
HonorHealth Research Institute
RECRUITINGPhoenix, Arizona, 85016, United States
Contact
Contact
-
Montefiore Medical Centre
RECRUITINGThe Bronx, New York, 10461, United States
Contact
Contact
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact
-
Next Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact
-
Precision NextGen Oncology & Research Center
RECRUITINGBeverly Hills, California, 90212, United States
Contact
Contact
-
Rhode Island Hospital
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
Contact
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14203, United States
Contact
Contact
-
Tennessee Oncology
RECRUITINGFranklin, Tennessee, 37067, United States
Contact
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77054, United States
Contact
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact